Nature's Ozempic: What And How You Eat Affects Your Weight Loss Journey
Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still prefer to lose weight without using medications. For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.
Increased intakes of fibre and monounsaturated fats (found in olive oil and avocadoes) - as well as the time of day when foods are eaten, the order that foods are eaten in, the speed of eating and even chewing - can naturally stimulate increased production of the same hormone responsible for the effects of semaglutide drugs.
As a family physician with a PhD in nutrition, I translate the latest nutrition science into dietary recommendations for my patients. A strategic approach to weight loss rooted in the latest science is not only superior to antiquated calorie counting, but also capitalizes on the same biological mechanisms responsible for the success of popular weight-loss drugs.
Semaglutide medications work by increasing the levels of a hormone called GLP-1 (glucagon-like peptide 1), a satiety signal that slows digestion and makes us feel full. These drugs also simultaneously decrease levels of an enzyme called DPP-4, which inactivates GLP-1.
As a result, this "stop eating" hormone that naturally survives for only a few minutes can survive for an entire week. This enables a semi-permanent, just-eaten sensation of fullness that consequently leads to decreased food intake and, ultimately, weight loss.
Nevertheless, medications aren't the only way to raise GLP-1 levels.
What You Eat
Fibre - predominantly found in beans, vegetables, whole grains, nuts and seeds - is the most notable nutrient that can significantly increase GLP-1. When fibre is fermented by the trillions of bacteria that live in our intestines, the resultant byproduct, called short chain fatty acids, stimulates the production of GLP-1.
This may explain why fibre consumption is one of the strongest predictors of weight loss and has been shown to enable weight loss even in the absence of calorie restriction.
Monounsaturated fats - found in olive oil and avocado oil - are another nutrient that raises GLP-1. One study showed that GLP-1 levels were higher following the consumption of bread and olive oil compared to bread and butter. Though notably, bread consumed with any kind of fat (be it from butter or even cheese) raises GLP-1 more than bread alone.
Another study showed that having an avocado alongside your breakfast bagel also increases GLP-1 more so than eating the bagel on its own. Nuts that are high in both fibre and monounsaturated fats, like pistachios, have also been shown to raise GLP-1 levels.
How You Eat
However, the specific foods and nutrients that influence GLP-1 levels are only half the story. GLP-1 is a good example of how it's not just what you eat that matters, it's also how you eat it.
Studies show that meal sequence - the order foods are eaten in - can impact GLP-1. Eating protein, like fish or meat, before carbohydrates, like rice, results in a higher GLP-1 level compared to eating carbohydrates before protein. Eating vegetables before carbohydrates has a similar effect.
Time of day also matters, because like all hormones, GLP-1 follows a circadian rhythm. A meal eaten at 8 a.m. stimulates a more pronounced release of GLP-1 compared to the same meal at 5 p.m. This may partly explain why the old saying "eat breakfast like a king, lunch like a prince and dinner like a pauper" is backed by evidence that demonstrates greater weight loss when breakfast is the largest meal of the day and dinner is the smallest.
The speed of eating can matter, too. Eating ice cream over 30 minutes has been shown to produce a significantly higher GLP-1 level compared to eating ice cream over five minutes. However, studies looking at blood sugar responses have suggested that if vegetables are eaten first, the speed of eating becomes less important.
Even chewing matters. One study showed that eating shredded cabbage raised GLP-1 more than drinking pureed cabbage.
Not As Potent As Medication
While certain foods and dietary strategies can increase GLP-1 naturally, the magnitude is far less than what is achievable with medications. One study of the GLP-1 raising effects of the Mediterranean diet demonstrated a peak GLP-1 level of approximately 59 picograms per millilitre of blood serum. The product monograph for Ozempic reports that the lowest dose produces a GLP-1 level of 65 nanograms per millilitre (one nanogram = 1,000 picograms). So medications raise GLP-1 more than one thousand times higher than diet.
Nevertheless, when you compare long-term risk for diseases like heart attacks, the Mediterranean diet lowers risk of cardiac events by 30 per cent, outperforming GLP-1 medications that lower risk by 20 per cent. While weight loss will always be faster with medications, for overall health, dietary approaches are superior to medications.
The following strategies are important for those trying to lose weight without a prescription:
Eat breakfast
Strive to make breakfast the largest meal of the day (or at least frontload your day as much as possible)
Aim to eat at least one fibre-rich food at every meal
Make olive oil a dietary staple
Be mindful of the order that you eat foods in, consume protein and vegetables before carbohydrates
Snack on nuts
Chew your food
Eat slowly
While natural approaches to raising GLP-1 may not be as potent as medications, they provide a drug-free approach to weight loss and healthy eating.
(Author: Mary J. Scourboutakos, Adjunct Lecturer in Family and Community Medicine, University of Toronto)
(Disclaimer: Mary J. Scourboutakos does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 hours ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
Time of India
2 hours ago
- Time of India
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly , the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Affordable Pre-Owned Jewelry in Great Condition in Malaysia Rings | Search Ads Search Now Undo The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. Live Events "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
Time of India
9 hours ago
- Time of India
Chemotherapy vs. Immunotherapy: Comparing effectiveness, side effects, and cancer treatment outcomes
Maintaining clear knowledge about cancer treatments is crucial for both patients and caregivers. Two of the most widely used approaches today are chemotherapy and immunotherapy. Tired of too many ads? go ad free now While both aim to control and eliminate cancer, they do so through fundamentally different mechanisms. Chemotherapy, in use for several decades, targets rapidly dividing cells—both cancerous and healthy—whereas immunotherapy represents a more recent breakthrough that harnesses the body's immune system to attack tumours naturally. This article explains how each treatment works, when they are used, their side effects, costs, and how they sometimes work together. The goal is to provide a comprehensive, up-to-date overview without any opinions—just clear facts based on current medical understanding. How chemotherapy works and when it is used in cancer treatment According to the Cancer Research Institute , chemotherapy uses drugs to kill cells that multiply quickly. This includes cancer cells but also healthy cells such as those in hair follicles, the gastrointestinal tract, and bone marrow. It relies on a cytotoxic effect that interferes with cell division or metabolism. Chemotherapy has historically been a first-line treatment for many cancers, including breast, lung, blood cancers, and others. Chemotherapy is administered in cycles over weeks or months, depending on the type and stage of cancer. It works systemically, meaning it can reach cancer cells throughout the body, making it useful for metastatic disease. For example, lung cancer and lymphoma are frequently treated with chemotherapy either alone or in combination with other therapies. Tired of too many ads? go ad free now What is immunotherapy and where it fits in for cancer treatment Immunotherapy does not directly attack cancer cells. Instead, it helps the immune system recognise and destroy tumours. Several forms are available today: Checkpoint inhibitors, which block proteins like PD-1, PD-L1, or CTLA-4, allow T-cells to attack tumours. CAR T‑cell therapy, including genetically modified T-cells tailored to recognise specific tumour antigens. Cancer vaccines are designed to stimulate an immune response against tumour-specific proteins. Cytokine therapy uses signalling molecules like interleukins to boost immune function. Oncolytic virus therapy, engineered viruses that kill cancer cells and trigger immunity. As per Cancer Research Institute , Immunotherapy is often used for cancers known to respond well, such as melanoma, non-small cell lung cancer, bladder cancer, certain lymphomas, and gastrointestinal tumours. It can be applied in advanced or metastatic stages or, increasingly, earlier in treatment plans. Recent regulatory approvals cover multiple cancers based on biomarkers like PD-L1 expression and microsatellite instability. Chemotherapy vs. Immunotherapy : Key differences in mechanism and effectiveness The main distinction lies in how the treatments target cancer: Chemotherapy directly attacks dividing cells, regardless of whether they are malignant or not. This leads to quick tumour shrinkage but also affects healthy tissues. Immunotherapy engages the immune system to fight cancer more selectively. It may take longer to produce measurable results, but in some cases, it provides durable remission. Effectiveness depends on tumour type, stage, and biomarker presence. For example, checkpoint inhibitors have shown significant long-term survival benefits in melanoma and lung cancer. However, immunotherapy is not universally effective: tumours lacking specific markers, or with low immune infiltration, may respond poorly. Combining Chemotherapy and Immunotherapy: Synergistic benefits Recent research shows that using both treatments together—known as chemoimmunotherapy—can improve outcomes for several hard-to-treat cancers. Chemotherapy may expose tumour antigens and modify the tumour microenvironment, making it easier for immune cells to act. Meanwhile, immunotherapy continues the attack. The combination is FDA-approved for cancers such as certain lung, head and neck, gastrointestinal cancers, and triple-negative breast cancer. Patients often experience better response rates and reduced drug resistance compared to using either therapy alone. Side effect profiles of immunotherapy and chemotherapy: What patients should expect Because of their different mechanisms, these treatments produce distinct side effects: Chemotherapy can cause hair loss, nausea, vomiting, fatigue, anaemia, immune suppression, mouth sores, nerve damage, and weight changes. These are often intense but may resolve after treatment ends. Immunotherapy may result in overactivation of the immune system, leading to inflammation in organs such as the lungs (pneumonitis), liver (hepatitis), colon (colitis), as well as flu-like symptoms, fatigue, skin reactions, or hormonal imbalance if endocrine glands are affected. Long-term monitoring is needed. Response time and duration of treatment Chemotherapy typically involves multiple treatment cycles and shows rapid effects, with measurable tumour reduction after a few weeks. Immunotherapy, particularly in advanced cancers, may have a delayed onset but can provide sustained responses extending for months or years. Maintenance treatment may also continue as immune surveillance. Immunotherapy and Chemotherapy costs and accessibility Treatment costs vary greatly. Chemotherapy is generally less expensive, especially in resource-limited settings. In India, a full course may range between Rs 50,000 and Rs 2,00,000 per cycle. Immunotherapy, being more complex and newer, is costlier—often Rs 2,50,000 to Rs 5,00,000 per cycle in such locations. Financial assistance or insurance coverage may be available. Effectiveness based on cancer type The success of each treatment depends significantly on cancer type: Immunotherapy shows outstanding results in MSI‑High colorectal cancer, with significantly better survival compared to chemotherapy. Studies show up to a 43% reduction in mortality risk in MSI‑High patients using immunotherapy. However, effectiveness in microsatellite-stable colorectal cancer remains modest. Pembrolizumab, a checkpoint inhibitor, led to complete responses in 59% of certain stage 2 or 3 bowel cancer patients before surgery, versus less than 5% using traditional chemotherapy. Patients with early-stage lung cancer treated with immunotherapy plus chemotherapy have seen survival improvements of nearly four months on average, compared to chemotherapy alone. Chemotherapy vs. Immunotherapy: Side-by-side comparison Feature Chemotherapy Immunotherapy Mechanism Direct cell-killing, non-selective Immune system activation, tumour-specific Onset of action Rapid tumour shrinkage Slower response, potentially long-lasting Side effects Hair loss, nausea, and immune suppression Immune-related inflammation, fatigue, skin issues Duration Fixed cycles over weeks/months Fewer treatments over months or years Cost Relatively lower Significantly higher per cycle Effective cancers Many solid and blood cancers Melanoma, lung, bladder, MSI-H colorectal, lymphoma Understanding the differences between immunotherapy and chemotherapy is important for treatment planning. Chemotherapy remains a fast and reliable option in many cancers, while immunotherapy offers a new era of personalised treatment with potentially lasting benefits. In some cases, combining both leads to the best outcomes. Each therapy comes with its risks, costs, and suitability profile. Ultimately, treatment decisions should be made by oncologists in consultation with patients, based on cancer type, biomarkers, overall health status, and patient preferences.
